Acceleron Pharma Announces Departure of Jasbir Seehra, Ph.D. Chief Scientific Officer

Acceleron Pharma Announces Departure of Jasbir Seehra, Ph.D. Chief Scientific Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 19, 2010 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced that Jasbir Seehra, Ph.D., Co-Founder and Chief Scientific Officer of Acceleron has decided to leave Acceleron to pursue other interests, although he will maintain a consulting relationship with the company.

"With the benefit of Jas' scientific leadership, Acceleron has rapidly developed a rich pipeline of novel therapeutic candidates, including three molecules in clinical development and several more at late preclinical stages," said John Knopf, Ph.D., Co-Founder and Chief Executive Officer of Acceleron. "He also showed his passion for patient care by championing the development of therapies for the treatment of Duchenne Muscular Dystrophy. Jas is a skilled corporate executive with tremendous entrepreneurial spirit and I wish him all the best as he seeks to repeat his successes at a new venture."

About Acceleron Pharma

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron's scientific approach takes advantage of its unique insight into the regenerative powers of the TGF-β superfamily of proteins. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For further information on Acceleron Pharma, please visit www.acceleronpharma.com

 

 

Contact: Acceleron Pharma, Inc.
Steven Ertel, 617-649-9234
Vice President, Corporate Development
or
Suda Communications LLC
Paul Kidwell (Media), 617-296-3854

 

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.